highly significantP < 0.0001
In the survival analysis, the log-rank, Cox-Tarone and Gehan-Breslow tests were all highly significant ( P < 0.0001) in favor of the robenacoxib group.
In the survival analysis, the log-rank, Cox-Tarone and Gehan-Breslow tests were all highly significant ( P < 0.0001) in favor of the robenacoxib group.